Christoph U. Correll, MD

Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York; Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York; Department of Child and Adolescent Psychiatry, Charité–Universitätsmedizin Berlin, Berlin, Germany; German Center for Mental Health (DZPG), Partner Site Berlin, Berlin, Germany

JCP
Consensus Statement

May 19, 2020

The quantification of antipsychotic levels in blood, or therapeutic drug monitoring (TDM), could aid clinicians in numerous challenging scenarios. Learn more about using TDM for dosing decisions in this...
Georgios Schoretsanitis, John M. Kane, Christoph U. Correll, et al
JCP
ASCP Corner

April 28, 2020

Antipsychotic polypharmacy in schizophrenia is common, but is it supported by evidence? And why is there an apparent disconnect between efficacy and effectiveness? This ASCP Corner article considers those...
Daniel Guinart, Christoph U. Correll
JCP
Educational Activity

April 14, 2020

Patient-reported outcomes are important for assessing the impact of schizophrenia and the success of treatment. Dr Correll discusses patient-centered care.
Christoph U. Correll
JCP
Educational Activity

April 14, 2020

New treatments for schizophrenia may improve symptom domains other than positive symptoms and reduce adverse effects. Here, an expert summarizes data on approved and investigational agents.
Christoph U. Correll
JCP
Original Research

March 17, 2020

People with psychotic disorders are more likely to have alcohol use disorder than the general population, but how does that comorbidity affect the course of their psychosis? This analysis...
Sanjeev Pathak, Ying Jiang, Lauren DiPetrillo, et al
JCP
Original Research

March 10, 2020

Alcohol use disorder is comorbid in 33% of US patients with schizophrenia. Testing the tolerability of olanzapine and samidorphan until the first event of exacerbation of disease symptoms is...
Mary F. Brunette, Christoph U. Correll, Stephanie S. O' Malley, et al
JCP
Academic Highlights

September 17, 2019

Long-acting injectable antipsychotics can be a powerful strategy in helping patients to receive ongoing benefit from treatment. You might think that you have adequately explained this treatment option to...
John M. Kane, Christoph U. Correll
JCP
Review Article

July 16, 2019

Transdermal delivery is an alternative to oral routes of drug administration. This delivery route has several innate advantages that may benefit patients with CNS disorders—read this Expert Commentary to...
Leslie Citrome, Courtney M. Zeni, Christoph U. Correll
JCP
Original Research

April 23, 2019

Read a study examining if patients in the early phase of schizophrenia would accept LAI antipsychotic treatment.
John M. Kane, Nina R. Schooler, Patricia Marcy, et al
JCP
Commentary

March 5, 2019

Read expert commentary on guidelines for treatment-resistant schizophrenia (TRS) to make more informed treatment decisions.
John M. Kane, Ofer Agid, Marjorie L. Baldwin, et al
JCP
Original Research

January 8, 2019

When treating patients with schizophrenia, achieving stable, long-term remission is an important step toward the goal of functional recovery. This study evaluated the effect of cariprazine on several measures...
Christoph U. Correll, Steven G. Potkin, Yan Zhong, et al
JCP
Original Research

December 18, 2018

Could valbenazine help your patients who experience antipsychotic-induced abnormal movements? This follow-up analysis of a phase 3 study provides further insights into the efficacy of valbenazine for tardive dyskinesia...
Christoph U. Correll, Andrew J. Cutler, John M. Kane, et al

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe